Is bendamustine used for multiple myeloma?
Bendamustine is a treatment option for patients with relapsed and refractory multiple myeloma in particular because of its low toxicity either as single agent or in combination.
What is 17p deletion myeloma?
The high-risk abnormality del(17p) can be detected by fluorescence in situ hybridization on malignant plasma cells (PCs) and has an adverse prognostic impact in patients with multiple myeloma (MM). Patients with del(17p) have reduced overall survival (OS).
What is Del 17p?
It is generally accepted that loss of the short arm of chromosome 17 [del(17p)], as determined by fluorescence in situ hybridization (FISH) analysis, is the most important high-risk factor in multiple myeloma, negatively impacting both progression-free survival (PFS) and overall survival (OS).
Is bendamustine well tolerated?
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood.
What is Penta refractory multiple myeloma?
And then there’s penta-refractory myeloma, which is myeloma that’s relapsed in spite of therapy with lenalidomide and pomalidomide (Pomalyst), as well as Velcade, or bortezomib and carfilzomib (Kyprolis), as well as CD38 antibody, they’re penta-refractory.
What do we do with chronic lymphocytic leukemia with 17p deletion?
Allogeneic stem-cell transplantation (alloSCT) remains the recommended strategy for patients with deletion 17p who achieve a CR. Because most patients with CLL are older than 60 years at the time of diagnosis, reduced-intensity conditioning regimens are typically employed.
How is 17p deletion detected?
To detect the 17p deletion, the chromosome G-banding (karyotype), FISH and arrays (SNP-array or CGH-array) or moderate or high-coverage read NGS (about 100 or more reads per base) are considered the most effective ones.
Does bendamustine cause neutropenia?
As with other cytotoxic therapies, bendamustine suppresses bone marrow function, resulting most commonly in thrombocytopenia, leukocytopenia, neutropenia, and anemia.
Does bendamustine cause anemia?
Bendamustine can cause severe autoimmune hemolytic anemia (AIHA), which may require plasma exchange and aggressive immunosuppression. Bendamustine-induced AIHA can be delayed, and many, but not all, cases report prior exposure to fludarabine.
What are the long term side effects of bendamustine?
You might have one or more of them.
- Hair loss or thinning. Your hair may thin.
- Difficulty sleeping. Talk to your doctor or nurse if you’re having problems sleeping.
- Heart palpitations or chest pain.
- Blood pressure changes.
- Liver changes.
- Allergic reaction.
What is triple class exposed multiple myeloma?
Patients with relapsed and refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options after exposure to an immunomodulatory drug, proteasome inhibitor (PI), and anti-CD38 antibody (triple-class exposure [TCE]).
What would be the preferred first line therapy for patients with mutated TP53 or 17p deletion?
For higher-risk patients with 17p and 11q deletion or TP53 mutation, Jain and Brown agreed that novel agents are the preferred course of therapy.
How do you investigate drug induced immune hemolytic anemia?
Drug-dependent antibodies are investigated by testing drug-treated red blood cells (RBCs) or by testing RBCs in the presence of a solution of drug. Drug-independent antibodies are serologically indistinct from idiopathic warm autoantibodies and cannot be defined or ex- cluded by serologic testing.